New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
06:18 EDTMDVNMedivation downgraded to Hold from Buy at Needham
Needham downgraded Medivation citing valuation as it believes near-term market dominance in the pre-chemo prostate cancer space is being priced into shares at current levels.
News For MDVN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
09:00 EDTMDVNPfizer has 'significant capacity' for additional deals, says JPMorgan
Subscribe for More Information
May 17, 2015
12:53 EDTMDVNMedivation, Astellas report enzalutamide study met primary endpoint
Subscribe for More Information
May 15, 2015
07:35 EDTMDVNMedivation price target raised to $148 from $128 at Leerink
Subscribe for More Information
May 14, 2015
07:07 EDTMDVNMedivation to present data in TNBC at ASCO
Medivation announced that the following abstract will be presented during an oral presentation at the 2015 American Society of Clinical Oncology, or ASCO, Annual Meeting on June 1, in Chicago: Results from a phase 2 study of enzalutamide, an androgen receptor, or AR, inhibitor, in advanced AR+ triple-negative breast cancer, or TNBC.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use